Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
ļ»æ

TSXV:VPT - Post by User

Post by jopatcloon Sep 11, 2024 1:04pm
55 Views
Post# 36218808

Ascend is he going to the Ollie Hinkle Heart Foundation šŸ¤”?

Ascend is he going to the Ollie Hinkle Heart Foundation šŸ¤”?Interesting Ascend is he going to the Ollie Hinkle Heart Foundation ?https://lnkd.in/gJBuiVn7 On Linkedin Kelly Yarnell (Kelly Yarnell .Regional Sales Manager ASCEND Cardiovascular,McNeese State University
OHHF is honored to have been invited to speak about our work at 3 pediatric cardiology conferences this Fall.

Our COO, Beth Rumack RN, MSN, MBA, NNP-BC, has been invited to present at The Fetal & Neonatal Cardiac Symposium in Chicago this September 21-23! She will delve into prenatal heart condition diagnosis and maternal and family mental well-being. Register now to be a part of this impactful gathering: https://lnkd.in/gJBuiVn7

Sydney Philpott-Streiff, MPH Director of Programs for OHHF will be speaking at the Cardiac Neurodevelopmental Outcome Collaborative’s (CNOC) conference 9/14. She’ll present on Ollie’s Branch and how this program supports the mental health of our community across the CHD journey. She will share the growth of the program over the last four years; where we are today and where we’re going; and how patients, families, and providers can access these valuable resources and get involved in OHHF’s mission.

On 10/26, Sydney, along with our Mental Health Strategy & Evaluation Manager, Laura Ulrich, will speak during the FON and NPC-QIC plenary session on Partnering for Emotional Health, with a focus on the need for cross-functional and interdisciplinary approaches to providing services for heart patients and their families from diagnosis through adulthood.

We couldn’t be more proud of you, Beth, Syd, and Laura! The heart community is lucky to have you in their corner, advocating for their needs and care.

<< Previous
Bullboard Posts
Next >>